BerandaA1LN34 • BVMF
add
Alnylam Pharmaceuticals Inc Bdr
Tutup sebelumnya
R$70,80
Rentang hari
R$70,80 - R$70,80
Rentang tahun
R$36,23 - R$85,44
Kapitalisasi pasar
31,18Â M USD
Volume Rata-Rata
37,00
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 593,17Â jt | 34,90% |
Biaya operasional | 595,51Â jt | 26,63% |
Laba bersih | -83,76Â jt | 39,24% |
Margin laba bersih | -14,12 | 54,96% |
Penghasilan per saham | 0,06 | 107,79% |
EBITDA | -90,99Â jt | 11,59% |
Tarif pajak efektif | 56,81% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 2,69Â M | 10,46% |
Total aset | 4,24Â M | 10,71% |
Total liabilitas | 4,17Â M | 3,02% |
Total ekuitas | 67,09 jt | — |
Saham yang beredar | 129,46 jt | — |
Harga terhadap nilai buku | 136,15 | — |
Tingkat pengembalian aset | -6,23% | — |
Tingkat pengembalian modal | -9,44% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -83,76Â jt | 39,24% |
Kas dari operasi | -94,66Â jt | -217,71% |
Kas dari investasi | -52,91Â jt | 78,01% |
Kas dari pembiayaan | 31,00Â jt | -20,98% |
Perubahan kas bersih | -133,85Â jt | 39,25% |
Arus kas bebas | -110,30Â jt | -165,23% |
Tentang
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
Didirikan
14 Jun 2002
Situs
Karyawan
2.230
